Immune-checkpoint blockade atezolizumab, a humanized anti-PD-L1 IgG1 antibody, combining with anti-VEGF-A antibody bevacizumab, has been approved by the FDA for the treatment of advanced unresectable or metastatic HCC [179,180]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.